Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date

Relapsed and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a heterogeneous disease previously associated with poor prognosis and limited treatment options until the advent and implementation of immune checkpoint inhibitors (ICIs). The fully humanized monoclonal antibody pembroli...

Descripción completa

Detalles Bibliográficos
Autores principales: McCusker, Michael G, Orkoulas-Razis, Dennis, Mehra, Ranee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153996/
https://www.ncbi.nlm.nih.gov/pubmed/32308436
http://dx.doi.org/10.2147/OTT.S196252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153996/
https://www.ncbi.nlm.nih.gov/pubmed/32308436
http://dx.doi.org/10.2147/OTT.S196252

Ejemplares similares